A comparative prospective study in the management of Helicobacter pylori infection using Lactobacillus reuteri Vs conventional therapy
Abstract
Background: Helicobacter pylori (H. pylori) infection has become a remarkable worldwide health problem. The eradication of H. pylori has become a challenge. Probiotics have proven beneficial in reducing the side effects and increases patient compliance. Lactobacillus reuteri (L. reuteri) is frequently used probiotic and considered safe for human consumption. The aim of this study was to compare the effectiveness of a probiotic and conventional antibiotic triple therapy in the management of H. pylori infection.
Methods: This was a prospective observational study carried out for a period of six months. Patient data were extracted from their medical records. Treatment outcome was evaluated based on the report of Rapid Urease Test (RUT). Symptoms were assessed using Gastrointestinal Symptom Rating Scale (GSRS). Descriptive statistics were used to summarize patient characteristics. T-test, chi square test and one way ANOVA were used wherever appropriate.
Results: A total of 105 patients with confirmed H. pylori infection were included, of which 42% were males and 58% were females. The mean age of three group patients were 38.03±10.68, 34.00±13.36 and 36.11±13.37 years. Eradication rate noted in Lactobacillus reuteri only treatment was 86%, eradication rate noted in Lactobacillus reuteri+ ppi was 86% and in antibiotic group was 92%. Patients with three different treatments have shown significant improvement in gastrointestinal symptoms (p < 0.001).
Conclusion: The overall data suggest that L. reuteri is recommended for a better eradication rate and reduced gastrointestinal symptoms. Though conventional triple therapy of H. pylori has shown an increased eradication rate and significant improvement in gastrointestinal symptoms, there was no great difference when compared with L. reuteri treated patients.
Keywords: H. pylori, Triple therapy, L. reuteri, Eradication, Gastrointestinal symptoms
Downloads
References
Vandenplas Y. Helicobacter pylori infection. World Journal of Gastroenterology. 2000; 6(1):20. https://doi.org/10.3748/wjg.v6.i1.20
JG K, AH van V, EJ K. Pathogenesis of Helicobacter pylori infection. Clinical microbiology reviews. 2006; 19(3):449-490. https://doi.org/10.1128/CMR.00054-05
LE W, RM P, KT W. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clinical microbiology reviews. 2010; 23(4):713-739. https://doi.org/10.1128/CMR.00011-10
Salih. Helicobacter pylori infection in developing countries: The burden for how long? Saudi Journal of Gastroenterology. 2009; 15(3):201. https://doi.org/10.4103/1319-3767.54743
Saleem N, Howden CW. Update on the Management of Helicobacter pylori Infection. Current Treatment Options in Gastroenterology. 2020; 18(3):1. https://doi.org/10.1007/s11938-020-00300-3
Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: Current and future insights. World Journal of Clinical Cases. 2016; 4(1):5. https://doi.org/10.12998/wjcc.v4.i1.5
Fijan S. Microorganisms with Claimed Probiotic Properties: An Overview of Recent Literature. International Journal of Environmental Research and Public Health. 2014; 11(5):4745. https://doi.org/10.3390/ijerph110504745
IAP M, LL P, DL D. Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia. Medicine and pharmacy reports. 2019; 92(4):352-355. https://doi.org/10.15386/mpr-1375
Holz C, Busjahn A, Mehling H, et al. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study. Probiotics and Antimicrobial Proteins. 2015; 7(2):91. https://doi.org/10.1007/s12602-014-9181-3
Emara MH, Mohamed SY, Abdel-Aziz HR. Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial. Therapeutic Advances in Gastroenterology. 2014; 7(1):4. https://doi.org/10.1177/1756283X13503514
JM HM. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. International journal of antimicrobial agents. 2003; 22(4):360-366. https://doi.org/10.1016/S0924-8579(03)00153-5
Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: Current status and future concepts. http://www.wjgnet.com/. 2014; 20(18):5283-5293. https://doi.org/10.3748/wjg.v20.i18.5283
M H, R O. Are probiotics useful in Helicobacter pylori eradication? World journal of gastroenterology. 2015; 21(37):10644-10653. https://doi.org/10.3748/wjg.v21.i37.10644
Macfarlane GT, Cummings JH. Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? BMJ : British Medical Journal. 1999; 318(7189):999. https://doi.org/10.1136/bmj.318.7189.999
Mu Q, Tavella VJ, Luo XM. Role of Lactobacillus reuteri in Human Health and Diseases. Frontiers in Microbiology. 2018; 0(APR):757. https://doi.org/10.3389/fmicb.2018.00757
Agah S, Khedmat H, Ghamar-Chehred ME, Hadi R, Aghaei A. Female gender and Helicobacter pylori infection, the most important predisposition factors in a cohort of gastric cancer: A longitudinal study. Caspian Journal of Internal Medicine. 2016; 7(2):136. Accessed August 17, 2021. /pmc/articles/PMC4913718/
DY G, M M. Helicobacter pylori urease for diagnosis of Helicobacter pylori infection: A mini review. Journal of advanced research. 2018; 13:51-57. https://doi.org/10.1016/j.jare.2018.01.006
EO A, MF D, T H, S B, AM A. The outcome of a 2-week treatment of Helicobacter pylori-positive duodenal ulcer with omeprazole-based antibiotic regimen in a region with high metronidazole resistance rate. European journal of gastroenterology & hepatology. 1999; 11(11):1259-1263. https://doi.org/10.1097/00042737-199911000-00013
Copyright (c) 2022 Syed Ibrahim Hassan, Mohammed Baleeqh Uddin, Mohd Ehtesham Kaunaine, Sumayya Sultana, Syeda Aleena Samreen, Mohd Mohiuddin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
. 